Please provide your email address to receive an email when new articles are posted on . The addition of carboplatin to paclitaxel improved pathologic complete response and EFS with no increase in ...

Please provide your email address to receive an email when new articles are posted on . Survival outcomes did not differ for patients with HNSCC who received radiotherapy with carboplatin-paclitaxel ...

Patient-reported outcomes (PROs) in locally advanced cervical cancer (LACC): Insights from the OUTBACK trial. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does ...

Outcomes of concurrent chemo-radiotherapy (CCRT) in locally advanced cervical cancer (LACC). Results of a retrospective analysis of a single institution No significant financial relationships to ...

The findings came from analyses of two national cancer registries. ILC accounts for about 10% of all newly diagnosed breast ...

Credit: GSK Dostarlimab plus carboplatin-paclitaxel reduced the risk of disease progression by 71% vs chemotherapy alone. The Food and Drug Administration (FDA) has approved Jemperli (dostarlimab) in ...

The DESTINY-Breast11 (DB-11) and DESTINY-Breast05 (DB-05) trials, presented at the European Society for Medical Oncology ...

Mairéad McInerney will never know if changes in her treatment plan have undercut her odds of surviving stage 3 triple-negative breast cancer. Critical shortages in cancer drugs have forced her to ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Kevin Kalinsky, MD ...

What’s important is that the patients enrolled into this trial are clearly representative of real-world patients that we are treating in our clinics every day,” said Rebecca A. Dent, MD.